500693-84-5Relevant academic research and scientific papers
METHODS OF REDUCING INFLAMMATION OF THE DIGESTIVE SYSTEM WITH INHIBITORS OF HIF-2-ALPHA
-
Paragraph 0281; 0282, (2019/10/23)
The present disclosure provides methods of reducing inflammation of the digestive system in a subject in need thereof, including subjects suffering from inflammatory bowel disease. Compositions for use in these methods are also provided.
COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF
-
Paragraph 0902, (2018/06/04)
The present invention provides methods and pharmaceutical compositions for treating proliferative disorders. The method involves step of administering to said subject a HIF-2alpha inhibitor and an immunotherapeutic agent.
COMPOSITIONS FOR USE IN TREATING PULMONARY ARTERIAL HYPERTENSION
-
Paragraph 00589, (2016/09/26)
The present disclosure provides methods of treating pulmonary arterial hypertension (PAH) in a subject in need thereof. Compositions for use in these methods are also provided.
AROMATIC COMPOUNDS AND USES THEREOF
-
Paragraph 0603; 0604, (2016/09/26)
Aromatic entities that modulate HIF-2α activity, pharmaceutical compositions containing the aromatic entities, and methods of using these chemical entities for treating proliferative diseases and conditions associated with HIF-2α activity are described herein.
COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA
-
Paragraph 00550, (2016/09/26)
The present disclosure provides methods of treating glioblastoma multiform (GBM) in a subject in need thereof. Compositions for use in these methods are also provided.
Structure-based drug design of tricyclic 8H-indeno[1,2-d][1,3]thiazoles as potent FBPase inhibitors
Tsukada, Tomoharu,Takahashi, Mizuki,Takemoto, Toshiyasu,Kanno, Osamu,Yamane, Takahiro,Kawamura, Sayako,Nishi, Takahide
scheme or table, p. 1004 - 1007 (2010/06/16)
With the goal of improving metabolic stability and further enhancing FBPase inhibitory activity, a series of tricyclic 8H-indeno[1,2-d][1,3]thiazoles was designed and synthesized with the aid of structure-based drug design. Extensive SAR studies led to th
Discovery of potent and orally active tricyclic-based FBPase inhibitors
Tsukada, Tomoharu,Kanno, Osamu,Yamane, Takahiro,Tanaka, Jun,Yoshida, Taishi,Okuno, Akira,Shiiki, Takeshi,Takahashi, Mizuki,Nishi, Takahide
experimental part, p. 5346 - 5351 (2010/09/05)
With the aim of exploring the effect of tricyclic-based FBPase inhibitors in cells and in vivo, a series of prodrugs of tricyclic phosphonates was designed and synthesized. Introducing prodrug moieties into tricyclic-based phosphonates led to the discover
